Oriola Oyj
0NES.L
London Stock Exchange0.93
EUR
+0.01
- -
Oriola Oyj
0NES.L
(London Stock Exchange)
Recent
price
0.93
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Oriola Oyj engages in the wholesale, distribution and advisory services for pharmaceuticals and health and wellbeing products across the Nordic region. The company offers a comprehensive portfolio of distribution services including GDP-compliant supply chain management, quality control, warehousing, logistics with modern cold chain technology and vaccine distribution expertise; wholesale services connecting suppliers and resellers of vitamins, food supplements, sports nutrients, wound care, beauty and makeup products, over-the-counter medicines and other health products with pharmacies, hospitals, veterinarians, retailers and e-commerce platforms; and advisory services spanning market entry, regulatory compliance, commercial strategy, market insights, medical information, patient support programmes, pharmacovigilance, real-world evidence and sales support for pharmaceutical companies throughout the product lifecycle. Oriola Oyj operates primarily in Finland and Sweden with additional presence in Denmark and Norway, serving as a key channel between manufacturers and end-users in the healthcare sector. Founded with roots in 1907 through Kronans Droghandel in Sweden and Oriola Oy in 1948 in Finland, the company is headquartered in Espoo, Finland, and maintains key facilities including distribution centres in Espoo and Enköping, a central warehouse in Mölnlycke and advisory operations in Herlev. In January 2025, Oriola Oyj acquired MedInfo ApS in Denmark to strengthen its Nordic footprint in medical information and patient support programmes; in November 2025, the company initiated change negotiations related to plans for a new distribution centre in Finland; and in 2023, it launched a refined strategy emphasizing its role as a leading specialist in pharmaceutical and health product wholesale with enhanced focus on core operations and customer value.